

104TH GENERAL ASSEMBLY

State of Illinois

2025 and 2026

HB3450

Introduced 2/18/2025, by Rep. Terra Costa Howard

SYNOPSIS AS INTRODUCED:

New Act
225 ILCS 60/54.5
720 ILCS 570/102

from Ch. 56 1/2, par. 1102

Creates the Naturopathic Medical Practice Act. Provides for the licensure of naturopathic doctors. Sets forth the qualifications for licensure. Provides the scope of practice of naturopathic doctors. Requires a person licensed under the Act to use specified titles and prohibits a person not licensed under the Act from using specified titles. Creates the Naturopathic Medical Board to oversee the licensure of naturopathic doctors and matters relating to training and licensure of naturopathic doctors. Sets forth the membership and duties of the Board. Contains provisions concerning approved naturopathic medical educational programs; displaying licenses; written collaboration agreements; prohibited actions by a licensee; exemptions; license expiration, renewal, denial, revocation, and continuing education; grounds for disciplinary action; investigations, notice, and hearings; records of proceedings at formal hearings; and confidentiality. Amends the Medical Practice Act of 1987. Authorizes physicians to collaborate with a naturopathic doctor in accordance with the requirements of the Naturopathic Medical Practice Act. Amends the Illinois Controlled Substances Act. Adds naturopathic doctors to meaning of "prescriber" and "prescription". Effective immediately.

LRB104 10056 AAS 20127 b

1 AN ACT concerning regulation.

2 **Be it enacted by the People of the State of Illinois,**
3 **represented in the General Assembly:**

4 Section 1. Short title. This Act may be cited as the
5 Naturopathic Medical Practice Act.

6 Section 5. Purpose and findings. The practice of
7 naturopathic medicine in the State is declared to affect the
8 public health, safety, and welfare and to be subject to
9 regulation and control in the public interest. It is further
10 declared to be a matter of public interest that naturopathic
11 doctors and the practice of naturopathic medicine, as defined
12 in this Act, merit the confidence of the public, that only
13 qualified persons be authorized to practice naturopathic
14 medicine in the State, and that no person shall practice
15 naturopathic medicine without a valid existing license to do
16 so.

17 The State is facing an unprecedented primary care shortage
18 in urban counties and an even higher shortage in rural
19 counties. Naturopathic doctors with a proper scope of practice
20 can help fill this void.

21 The General Assembly recognizes that naturopathic doctors
22 comprise a distinct health care profession that affects the
23 public health, safety, and welfare and that licensure of

1 naturopathic doctors will increase freedom of choice in health
2 care and help address the primary care shortage in the State.
3 This Act shall be liberally construed to best carry out these
4 subjects and purposes.

5 Section 10. Definitions. In this Act:

6 "Approved naturopathic medical educational program" means
7 an educational program that the Board has approved as meeting
8 the requirements of Section 20 of this Act and that prepares
9 naturopathic doctors for the practice of naturopathic
10 medicine.

11 "Association" means an entity that is approved by the
12 American Association of Naturopathic Physicians and that
13 represents the interests of naturopathic doctors in this
14 State.

15 "Board" means the Naturopathic Medical Board established
16 under Section 80 of this Act.

17 "Clinical laboratory procedure" means the use of
18 venipuncture consistent with naturopathic medical practice,
19 commonly used diagnostic modalities consistent with
20 naturopathic practice, the recording of a patient's health
21 history, physical examination, ordering and interpretation of
22 radiographic diagnostics, and other standard imaging and
23 examination of body orifices, excluding endoscopy and
24 colonoscopy. "Clinical laboratory procedure" includes the
25 practice of obtaining samples of human tissues, except

1 surgical excision beyond surgical excision that is authorized
2 as a minor office procedure.

3 "Department" mean the Department of Financial and
4 Professional Regulation.

5 "Homeopathic medicine" means a system of medicine based on
6 the use of infinitesimal doses of substances capable of
7 producing symptoms similar to those of the disease treated, as
8 listed in the Homeopathic Pharmacopoeia of the United States.

9 "Hygiene" means the use of preventive techniques,
10 including personal hygiene for asepsis, public health, and
11 safety.

12 "Laboratory examination" means:

- 13 (1) phlebotomy;
14 (2) a clinical laboratory procedure;
15 (3) an orificial examination;
16 (4) a physiological function test; and
17 (5) a screening or test that is consistent with
18 naturopathic education and training.

19 "Legend drug" has the same meaning as set forth in Section
20 3.23 of the Illinois Food, Drug and Cosmetic Act.

21 "License" means a license issued by the Board to an
22 individual pursuant to this Act and rules authorizing that
23 individual to practice naturopathic medicine in this State.

24 "Licensee" means a naturopathic doctor licensed by the
25 Board to practice naturopathic medicine in this State.

26 "Minor office procedure" includes:

1 (1) the treatment of superficial lacerations, lesions,
2 or abrasions, excluding surgical care to treat a lesion
3 suspected of malignancy;

4 (2) the removal of foreign bodies located in
5 superficial structures, excluding the globe of the eye;

6 (3) trigger point therapy;

7 (4) dermal stimulation; and

8 (5) the use of antiseptics and topical or local
9 anesthetics.

10 "Naturopathic doctor" means an individual licensed under
11 this Act as a naturopathic doctor to practice naturopathic
12 medicine in this State as a primary care provider.

13 "Naturopathic medicine" means:

14 (1) a system of health care for the prevention,
15 diagnosis, and treatment of human health conditions,
16 injury, and disease;

17 (2) the promotion or restoration of health; and

18 (3) the support and stimulation of a patient's
19 inherent self-healing processes through patient education
20 and the use of naturopathic therapies and therapeutic
21 substances.

22 "Naturopathic physical medicine" means the use of one or
23 more of the following physical agents in a manner consistent
24 with naturopathic medical practice on a part or the whole of
25 the body, by hand or by mechanical means, in the resolution of
26 a human ailment or conditions:

- (1) air;
- (2) water;
- (3) heat;
- (4) cold;
- (5) sound;
- (6) light;
- (7) electromagnetism;
- (8) soft tissue therapy;
- (9) joint mobilization;
- (10) therapeutic exercise; or
- (11) naturopathic manipulation.

"Naturopathic therapy" means the use of:

- (1) naturopathic physical medicine;
- (2) suggestion;
- (3) hygiene;
- (4) a therapeutic substance;
- (5) nutrition and food science;
- (6) homeopathic medicine;
- (7) a clinical laboratory procedure; or
- (8) a minor office procedure.

"Nutrition and food science" means the prevention and treatment of disease or other human conditions through the use of food, water, herbs, roots, bark, or natural food elements.

"Prescription" has the same meaning as set forth in Section 3 of the Pharmacy Practice Act.

"Professional examination" means a competency based

1 naturopathic doctor licensing examination as determined by
2 Department rule.

3 "Suggestion" means a technique using:

- 4 (1) biofeedback;
- 5 (2) health education; or
- 6 (3) health counseling.

7 "Telehealth" or "telepractice" means the delivery of
8 services under this Act by using electronic communication,
9 information technologies, or other means between an individual
10 licensed under this Act in one location and a patient or client
11 in another location, with or without an intervening healthcare
12 provider. "Telehealth" or "telepractice" includes direct,
13 interactive patient encounters, asynchronous
14 store-and-forward technologies, and remote monitoring.
15 Telehealth or telepractice is not prohibited under this Act if
16 the provision of telehealth or telepractice services is
17 appropriate for the client and the level of care provided
18 meets the required level of care for that client. Individuals
19 providing services regulated by this Act via telepractice
20 shall comply with and are subject to all licensing and
21 disciplinary provisions of this Act.

22 "Therapeutic substance" means any of the following
23 exemplified in a standard naturopathic medical text, journal,
24 or pharmacopoeia:

- 25 (1) a vitamin;
- 26 (2) a mineral;

- 1 (3) a nutraceutical;
- 2 (4) a botanical medicine;
- 3 (5) oxygen;
- 4 (6) a homeopathic medicine;
- 5 (7) a hormone;
- 6 (8) a hormonal or pharmaceutical contraceptive device;
- 7 (9) an enzyme; or
- 8 (10) other physiologic substance.

9 Section 15. Qualifications for licensure. The Board shall
10 license an applicant who:

11 (1) submits, in accordance with rules of the
12 Department, the following items to the Board:

13 (A) an application for licensure designed and
14 approved by the Board and submitted in accordance with
15 rules of the Department;

16 (B) an application fee submitted in an amount and
17 manner established by rules of the Department;

18 (C) evidence that the applicant has graduated from
19 a Council on Naturopathic Medical Education or an
20 equivalent federally recognized accrediting body,
21 approved naturopathic medical education program;

22 (D) evidence that the applicant has passed a
23 professional examination authorized by rule of the
24 Department and administered by the North American
25 Board of Naturopathic Examiners or its successor;

1 (E) evidence that the applicant has passed a minor
2 surgery examination authorized by rules of the
3 Department and administered by the North American
4 Board of Naturopathic Examiners or its successor; and

5 (F) evidence that the applicant has passed a
6 jurisprudence examination conducted by the
7 Naturopathic Medical Board;

8 (2) is determined by the Board to be physically and
9 mentally capable of safely practicing naturopathic
10 medicine with or without reasonable accommodation; and

11 (3) has not had a license to practice naturopathic
12 medicine or other health care license, registration, or
13 certificate refused, revoked, or suspended by any other
14 jurisdiction for reasons that relate to the applicant's
15 ability to skillfully and safely practice naturopathic
16 medicine unless that license, registration, or
17 certification has been restored to good standing by that
18 jurisdiction.

19 Section 20. Approved naturopathic medical educational
20 program. The Department shall establish, by rule, guidelines
21 for an approved naturopathic medical educational program,
22 which guidelines shall meet the following requirements and the
23 Department's specifications for the education of naturopathic
24 doctors. The approved naturopathic medical educational program
25 shall:

1 (1) offer graduate-level, full-time didactic and
2 supervised clinical training;

3 (2) be accredited, or have achieved candidacy status
4 for accreditation, by the Council on Naturopathic Medical
5 Education or an equivalent federally recognized
6 accrediting body for naturopathic medical programs that is
7 also recognized by the Department; and

8 (3) be conducted by an institution of higher
9 education, or a division of an institution of higher
10 education, that:

11 (A) is accredited or is a candidate for
12 accreditation by a regional or national institutional
13 accrediting agency recognized by the United States
14 Secretary of Education or a diploma-granting,
15 degree-equivalent college or university; or

16 (B) meets equivalent standards for recognition of
17 accreditation established by rules of the Department
18 for medical education programs offered in Canada.

19 Section 25. Display of license. A licensee shall display
20 the licensee's license in the licensee's place of business in
21 a location clearly visible to the licensee's patients and
22 shall also display evidence of the licensee having completed
23 an approved naturopathic medical educational program.

24 Section 30. Written collaborative agreements; prescriptive

1 authority.

2 (a) A written collaborative agreement is required for all
3 naturopathic doctors to practice in the State, except as
4 provided in Section 35 and Section 40.

5 (b) A written collaborative agreement shall describe the
6 working relationship of the naturopathic doctor with the
7 collaborating physician and shall describe the categories of
8 care, treatment, or procedures to be provided by the
9 naturopathic doctor. The written collaborative agreement shall
10 promote the exercise of professional judgment by the
11 naturopathic doctor commensurate with his or her education,
12 training and experience. The services to be provided by the
13 naturopathic doctor shall be services that the collaborating
14 physician is authorized to and generally provides to his or
15 her patients in the normal course of his or her clinical
16 medical practice. The written collaborative agreement need not
17 describe the exact steps that a naturopathic doctor must take
18 with respect to each specific condition, disease, or symptom
19 but must specify which authorized procedures require the
20 presence of the collaborating physician as the procedures are
21 being performed. The relationship under a written
22 collaborative agreement shall not be construed to require the
23 personal presence of a physician at the place where services
24 are rendered. Methods of communication shall be available for
25 consultation with the collaborating physician in person or by
26 telecommunications or electronic communications as set forth

1 in the written collaborative agreement. For the purposes of
2 this Section, "generally provides to his or her patients in
3 the normal course of his or her clinical medical practice"
4 means services, not specific tasks or duties, the
5 collaborating physician routinely provides individually or
6 through delegation to other persons so that the physician has
7 the experience and ability to collaborate and provide
8 consultation.

9 (c) The written collaborative agreement shall be adequate
10 if a physician:

11 (1) participates in the joint formulation and joint
12 approval of orders or guidelines with the naturopathic
13 doctor and he or she periodically reviews such orders and
14 the services provided patients under such orders in
15 accordance with accepted standards of medical practice and
16 naturopathic doctor practice; and

17 (2) provides consultation at least once a month.

18 (d) A copy of the signed, written collaborative agreement
19 must be available to the Department upon request from both the
20 naturopathic doctor and the collaborating physician.

21 (e) A naturopathic doctor shall inform each collaborating
22 physician of all written collaborative agreements he or she
23 has signed and provide a copy of these to any collaborating
24 physician upon request.

25 (f) A collaborating physician may, but is not required to,
26 delegate prescriptive authority to a naturopathic doctor as

1 part of a written collaborative agreement. This authority may,
2 but is not required to, include prescription of, selection of,
3 orders for, administration of, storage of, acceptance of
4 samples of, and dispensing medical devices, over-the-counter
5 medications, legend drugs excluding controlled substances, and
6 other preparations, including, but not limited to, botanical
7 and herbal remedies.

8 (g) The collaborating physician shall file with the
9 Department notice of delegation of prescriptive authority to a
10 naturopathic doctor and termination of delegation, specifying
11 the authority delegated or terminated. Nothing in this Act
12 shall be construed to limit the delegation of tasks or duties
13 by the collaborating physician to a nurse or other
14 appropriately trained persons in accordance with Section 54.2
15 of the Medical Practice Act of 1987.

16 (h) Nothing in this Act shall be construed to limit the
17 delegation of tasks or duties by a physician to a licensed
18 practical nurse, a registered professional nurse, or other
19 persons. Nothing in this Act shall be construed to limit the
20 method of delegation that may be authorized by any means,
21 including, but not limited to, oral, written, electronic,
22 standing orders, protocols, guidelines, or verbal orders.
23 Nothing in this Act shall be construed to authorize a
24 naturopathic doctor to provide health care services required
25 by law or rule to be performed by a physician. Nothing in this
26 Act shall be construed to authorize the delegation or

1 performance of operative surgery.

2 Section 35. Written collaborative agreement; temporary
3 practice. Any naturopathic doctor required to enter into a
4 written collaborative agreement with a collaborating physician
5 is authorized to continue to practice for up to 90 days after
6 the termination of a written collaborative agreement provided
7 the naturopathic doctor seeks any necessary collaboration at a
8 local hospital and refers patients who require services beyond
9 the training and experience of the naturopathic doctor to a
10 physician or other health care provider.

11 Section 40. Written collaborative agreement exemptions. A
12 naturopathic doctor shall be exempt from a written
13 collaborative agreement and granted full practice authority if
14 the naturopathic doctor meets either of the following:

15 (1) possesses a minimum of 2 years practicing in a
16 state with prescriptive authority; or

17 (2) has completed an internship or residency that had
18 a duration of at least one year.

19 Section 45. Full practice authority.

20 (a) A naturopathic doctor shall be deemed by law to
21 possess the ability to practice without a written
22 collaborative agreement if the naturopathic doctor files with
23 the Department a notarized attestation of completion of at

1 least 100 hours of continuing education or training and at
2 least 2,000 hours of clinical experience. Documentation of
3 successful completion of the continuing education hours shall
4 be provided to the Department upon request. Completion of the
5 clinical experience must be attested to by the collaborating
6 physician or physicians or employer and the naturopathic
7 doctor. If the collaborating physician or physicians or
8 employer is unable to attest to the completion of the clinical
9 experience, the Department may accept other evidence of
10 clinical experience as established by rule.

11 (b) The scope of practice of a naturopathic doctor with
12 full practice authority includes the following:

- 13 (1) all matters included in Section 50;
14 (2) practicing without a written collaborative
15 agreement in all practice settings;
16 (3) authority to prescribe legend drugs, excluding
17 controlled substances, over-the-counter medications, and
18 other preparations, including, but not limited to,
19 botanical and herbal remedies; and
20 (4) use of only local anesthetic.

21 The scope of practice of a naturopathic doctor does not
22 include operative surgery.

23 (c) The Department may adopt rules necessary to administer
24 this Section, including, but not limited to, requiring the
25 completion of forms and the payment of fees.

26 (d) Nothing in this Act shall be construed to authorize a

1 naturopathic doctor with full practice authority to provide
2 health care services required by law or rule to be performed by
3 a physician.

4 Section 50. Scope of practice. A licensee may practice
5 naturopathic medicine to provide primary care in alignment
6 with naturopathic medical education to:

7 (1) perform physical examinations;

8 (2) order laboratory examinations;

9 (3) order diagnostic imaging studies;

10 (4) interpret the results of laboratory examinations
11 for diagnostic purposes;

12 (5) order and, based on a radiologist's report, take
13 action on diagnostic imaging studies in a manner
14 consistent with naturopathic training;

15 (6) prescribe, administer, dispense, and order food,
16 extracts of food, nutraceuticals, vitamins, amino acids,
17 minerals, enzymes, botanicals and their extracts,
18 botanical medicines, homeopathic medicines, dietary
19 supplements, and nonprescription drugs as defined by the
20 Federal Food, Drug, and Cosmetic Act;

21 (7) use routes of administration that include oral,
22 nasal, auricular, subcutaneous, intravenous, transdermal,
23 and intramuscular routes of administration, consistent
24 with the education and training of a naturopathic doctor;

25 (8) perform naturopathic physical medicine;

(9) employ the use of naturopathic therapy;

(10) use therapeutic devices, barrier contraception, hormonal and pharmaceutical contraception, and durable medical equipment; or

Section 55. Referral requirement. If a patient's medical condition is determined, at the time of evaluation or treatment, to be beyond the scope of practice of a licensee, then the licensee must refer the patient to a physician licensed to practice medicine in all of its branches under the Medical Practice Act of 1987 or an advanced practice registered nurse licensed under the Nurse Practice Act.

Section 56. Prohibitions. A licensee shall not:

(1) perform major surgery;

(2) use general or spinal anesthetics;

(3) administer ionizing radioactive substances for therapeutic purposes;

(4) perform a surgical procedure using a laser device;

(5) perform a surgical procedure involving any of the following areas of the body that extend beyond superficial tissue:

(A) eyes;

(B) ears;

(C) tendons;

(D) nerves;

- 1 (E) veins; or
- 2 (F) arteries;
- 3 (6) perform a surgical abortion;
- 4 (7) treat any lesion suspected of malignancy or
- 5 requiring surgical removal; or
- 6 (8) perform acupuncture.

7 Section 70. Exemptions. Nothing in this Act shall be
8 construed to prohibit or to restrict:

9 (1) the practice of a health care profession by an
10 individual who is licensed, certified, or registered under
11 other laws of this State and who is performing services
12 within the individual's authorized scope of practice;

13 (2) the practice of naturopathic medicine by a student
14 enrolled in an approved naturopathic medical educational
15 program if the practice of naturopathic medicine by a
16 student is performed pursuant to a course of instruction
17 or an assignment from an instructor at an accredited
18 university or college by an instructor duly licensed as a
19 health care provider in this State;

20 (3) any person who sells a vitamin or herb from
21 providing information about the vitamin or herb;

22 (4) the practice of naturopathic medicine by persons
23 who are licensed to practice in any other state or
24 district in the United States and who enter this State to
25 consult with a naturopathic doctor of this State if the

1 consultation is limited to an examination or
2 recommendation; or

3 (5) any person or practitioner who is not licensed as
4 a naturopathic doctor from recommending ayurvedic
5 medicine, herbal remedies, nutritional advice, homeopathy,
6 or other therapy that is within the scope of practice of
7 naturopathic medicine; however, the person or practitioner
8 shall not:

9 (A) use a title protected pursuant to Section 75;

10 (B) represent or assume the character or
11 appearance of a licensee; or

12 (C) otherwise use a name, title, or other
13 designation that indicates or implies that the person
14 is a licensee.

15 Section 75. Protected titles.

16 (a) A licensee shall use the title "naturopathic doctor"
17 and the recognized abbreviation "N.D.".

18 (b) A licensee has the exclusive right to use the
19 following terms in reference to the licensee's self:

20 (1) "naturopathic doctor";

21 (2) "doctor of naturopathic medicine";

22 (3) "doctor of naturopathy";

23 (4) "naturopath";

24 (5) "N.D."; and

25 (6) "ND".

1 (c) An individual represents the individual's self to be a
2 naturopathic doctor when the individual uses or adopts any of
3 the following terms in reference to the individual's self:

- 4 (1) "naturopathic doctor";
- 5 (2) "doctor of naturopathic medicine";
- 6 (3) "doctor of naturopathy";
- 7 (4) "naturopath";
- 8 (5) "N.D."; or
- 9 (6) "ND".

10 (d) An individual shall not represent the individual's
11 self to the public as a naturopathic doctor, a doctor of
12 naturopathic medicine, a doctor of naturopathy, a naturopath,
13 a naturopathic medical doctor, a naturopathic physician, or as
14 being otherwise authorized to practice naturopathic medicine
15 in this State, unless the individual is a licensee.

16 Section 80. Naturopathic Medical Board.

17 (a) The Naturopathic Medical Board shall oversee:

- 18 (1) licensure of naturopathic doctors; and
- 19 (2) matters relating to training and licensure of
20 naturopathic doctors.

21 (b) Within 180 days after the effective date of this Act,
22 the Governor shall appoint an initial Board consisting of 2
23 members for terms of 4 years each, 3 members for terms of 3
24 years each, and 4 members for terms of 2 years each. The
25 initial Board shall consist of the following voting members:

1 (1) 5 licensed naturopathic doctors who are residents
2 of this State;

3 (2) 2 practicing physicians licensed to practice
4 medicine in all of its branches; and

5 (3) 2 public members who are residents of this State,
6 who are not, and never have been, a licensed health care
7 practitioner, and who do not have an interest in
8 naturopathic education, naturopathic medicine, or
9 naturopathic business or practice.

10 Members of the Board may be recommended to the Governor by
11 the Illinois Association of Naturopathic Physicians.

12 (c) As the terms of the initial Board members expire, the
13 Governor shall appoint successors for terms of 4 years each as
14 follows:

15 (1) 5 naturopathic doctors licensed pursuant to this
16 Act;

17 (2) 2 practicing physicians licensed to practice
18 medicine in all of its branches with experience working
19 with naturopathic doctors; and

20 (3) 2 public members that are residents of this State
21 who are not, and never have been, a licensed health care
22 practitioner and who do not have an interest in
23 naturopathic education, naturopathic medicine, or
24 naturopathic business or practice.

25 (d) Within 30 days after the Board is established, the
26 Board shall call the first meeting, at which meeting members

1 shall elect a chair. The Board may hold meetings at the call of
2 the chair or at the written request of any 2 members of the
3 Board.

4 (e) Vacancies on the Board shall be filled from a list of
5 not fewer than 3 candidates.

6 (f) A majority of the Board shall constitute a quorum.

7 (g) Members of the Board shall serve without compensation
8 but may, at the discretion of the Board, be reimbursed for
9 their expenses incurred in performing their duties.

10 (h) The Department of Financial and Professional
11 Regulation shall provide administrative and other support to
12 the Board.

13 Section 85. Board duties. The Board shall have the
14 following duties:

15 (1) regulating the licensure of naturopathic doctors
16 and determining the hours of continuing education units
17 required for maintaining licensure as a naturopathic
18 doctor;

19 (2) prescribing the manner in which records of
20 examinations and treatments shall be kept and maintained;

21 (3) establishing standards for professional
22 responsibility and conduct;

23 (4) identifying disciplinary actions and circumstances
24 that require disciplinary action;

25 (5) developing a means to provide information to all

1 licensees in this State;

2 (6) providing for the investigation of complaints
3 against licensees or persons holding themselves out as
4 naturopathic doctors in this State;

5 (7) providing for the publication of information for
6 the public about licensees and the practice of
7 naturopathic medicine in this State;

8 (8) providing for an orderly process for reinstatement
9 of a license;

10 (9) establishing criteria for advertising or
11 promotional materials;

12 (10) establishing procedures and standards for
13 reviewing licensing examination scores;

14 (11) establishing procedures for reviewing transcripts
15 demonstrating completion of the approved naturopathic
16 medical educational program;

17 (12) establishing and maintaining a list of
18 naturopathic medical education programs that meet the
19 requirements of Section 20;

20 (13) establishing the requirements for issuance and
21 renewal of licenses;

22 (14) creating and conducting the jurisprudence
23 examination; and

24 (15) any other matter necessary to implement this Act.

25 Section 90. License expiration, renewal, denial,

1 revocation, and continuing education.

2 (a) A license issued or renewed pursuant to this Act shall
3 expire in a time frame determined by rule by the Department.

4 (b) The Board may renew the license of any licensee who,
5 upon the expiration of the licensee's license:

6 (1) has submitted an application for renewal;

7 (2) has paid the renewal fee established by rules of
8 the Department;

9 (3) meets the qualifications for licensure set forth
10 in this Act and rules of the Department; and

11 (4) meets the continuing education requirements
12 established by the Board.

13 (c) If the Board intends to refuse to issue or renew,
14 revoke, or suspend a license, the Department shall grant the
15 applicant or licensee an opportunity for a hearing.

16 Section 95. Grounds for disciplinary action.

17 (a) The Department may refuse to issue or to renew, or may
18 revoke, suspend, place on probation, reprimand, or take other
19 disciplinary or nondisciplinary action with regard to any
20 license issued under this Act as the Department may deem
21 proper, including the issuance of fines not to exceed \$10,000
22 for each violation, for any one or combination of the
23 following causes:

24 (1) material misstatement in furnishing information to
25 the Department;

1 (2) violations of this Act, or the rules adopted under
2 this Act;

3 (3) conviction by plea of guilty or nolo contendere,
4 finding of guilt, jury verdict, or entry of judgment or
5 sentencing, including, but not limited to, convictions,
6 preceding sentences of supervision, conditional discharge,
7 or first offender probation, under the laws of any
8 jurisdiction of the United States that is: (i) a felony;
9 or (ii) a misdemeanor, an essential element of which is
10 dishonesty, or that is directly related to the practice of
11 the profession;

12 (4) making any misrepresentation for the purpose of
13 obtaining licenses;

14 (5) professional incompetence;

15 (6) aiding or assisting another person in violating
16 any provision of this Act or its rules;

17 (7) failing, within 60 days, to provide information in
18 response to a written request made by the Department;

19 (8) engaging in dishonorable, unethical, or
20 unprofessional conduct, as defined by rule, of a character
21 likely to deceive, defraud, or harm the public.

22 (9) habitual or excessive use or addiction to alcohol,
23 narcotics, stimulants, or any other chemical agent or drug
24 that results in a naturopathic doctor's inability to
25 practice with reasonable judgment, skill, or safety;

26 (10) discipline by another U.S. jurisdiction or

1 foreign nation, if at least one of the grounds for
2 discipline is the same or substantially equivalent to
3 those set forth in this Section;

4 (11) directly or indirectly giving to or receiving
5 from any person, firm, corporation, partnership, or
6 association any fee, commission, rebate or other form of
7 compensation for any professional services not actually or
8 personally rendered. Nothing in this paragraph (11)
9 affects any bona fide independent contractor or employment
10 arrangements, which may include provisions for
11 compensation, health insurance, pension, or other
12 employment benefits, with persons or entities authorized
13 under this Act for the provision of services within the
14 scope of the licensee's practice under this Act;

15 (12) abandonment of a patient;

16 (13) willfully making or filing false records or
17 reports in the individual's practice, including, but not
18 limited to, false records filed with State agencies or
19 departments;

20 (14) physical illness, or mental illness or impairment
21 that results in the inability to practice the profession
22 with reasonable judgment, skill, or safety, including, but
23 not limited to, deterioration through the aging process or
24 loss of motor skill;

25 (15) being named as a perpetrator in an indicated
26 report by the Department of Children and Family Services

1 under the Abused and Neglected Child Reporting Act, and
2 upon proof by clear and convincing evidence that the
3 licensee has caused a child to be an abused child or
4 neglected child as defined in the Abused and Neglected
5 Child Reporting Act;

6 (16) gross negligence resulting in permanent injury or
7 death of a patient;

8 (17) employment of fraud, deception or any unlawful
9 means in applying for or securing a license under this
10 Act;

11 (18) immoral conduct in the commission of any act,
12 such as sexual abuse, sexual misconduct, or sexual
13 exploitation related to the licensee's practice;

14 (19) practicing under a false or assumed name, except
15 as provided by law;

16 (20) making a false or misleading statement regarding
17 the licensee's skill or the efficacy or value of the
18 treatment or remedy prescribed by the licensee in the
19 course of treatment;

20 (21) allowing another person to use the licensee's
21 license to practice;

22 (22) prescribing, selling, administering,
23 distributing, giving, or self-administering a drug
24 classified as a controlled substance;

25 (23) a pattern of practice or other behavior that
26 demonstrates incapacity or incompetence to practice under

1 this Act;

2 (24) violating State or federal laws or regulations
3 relating to controlled substances or other legend drugs or
4 ephedra as defined in the Ephedra Prohibition Act;

5 (25) failure to establish and maintain records of
6 patient care and treatment as required by law;

7 (26) attempting to subvert or cheat on the required
8 examinations;

9 (27) willfully failing to report an instance of
10 suspected abuse, neglect, financial exploitation, or
11 self-neglect of an eligible adult as defined in and
12 required by the Adult Protective Services Act;

13 (28) being named as an abuser in a verified report by
14 the Department on Aging under the Adult Protective
15 Services Act and upon proof by clear and convincing
16 evidence that the licensee abused, neglected, or
17 financially exploited an eligible adult as defined in the
18 Adult Protective Services Act;

19 (29) failure to report to the Department an adverse
20 final action taken against the individual by another
21 licensing jurisdiction of the United States or a foreign
22 state or country, a peer review body, a health care
23 institution, a professional society or association, a
24 governmental agency, a law enforcement agency, or a court
25 acts or conduct similar to acts or conduct that would
26 constitute grounds for action under this Section; and

1 (30) failure to provide copies of records of patient
2 care or treatment, except as required by law.

3 (b) The Department may refuse to issue or may suspend
4 without hearing, as provided for in the Code of Civil
5 Procedure, the license of any person who fails to file a
6 return, or pay the tax, penalty, or interest shown in a filed
7 return, or pay any final assessment of the tax, penalty, or
8 interest as required by any tax Act administered by the
9 Illinois Department of Revenue, until the requirements of any
10 such tax Act are satisfied in accordance with subsection (g)
11 of Section 2105-15 of the Civil Administrative Code of
12 Illinois.

13 (c) The determination by a circuit court that a licensee
14 is subject to involuntary admission or judicial admission as
15 provided in the Mental Health and Developmental Disabilities
16 Code operates as an automatic suspension. The suspension will
17 end only upon a finding by a court that the patient is no
18 longer subject to involuntary admission or judicial admission
19 and issues an order so finding and discharging the patient,
20 and upon the recommendation of the Board to the Department
21 that the licensee be allowed to resume the licensee's
22 practice.

23 (d) In enforcing this Section, the Department upon a
24 showing of a possible violation may compel an individual
25 licensed to practice under this Act, or who has applied for
26 licensure under this Act, to submit to a mental or physical

1 examination, or both, which may include a substance abuse or
2 sexual offender evaluation, as required by and at the expense
3 of the Department.

4 The Department shall specifically designate the examining
5 physician licensed to practice medicine in all of its branches
6 or, if applicable, the multidisciplinary team involved in
7 providing the mental or physical examination or both. The
8 multidisciplinary team shall be led by a physician licensed to
9 practice medicine in all of its branches and may consist of one
10 or more or a combination of physicians licensed to practice
11 medicine in all of its branches, licensed clinical
12 psychologists, licensed clinical social workers, licensed
13 clinical professional counselors, and other professional and
14 administrative staff. Any examining physician or member of the
15 multidisciplinary team may require any person ordered to
16 submit to an examination pursuant to this Section to submit to
17 any additional supplemental testing deemed necessary to
18 complete any examination or evaluation process, including, but
19 not limited to, blood testing, urinalysis, psychological
20 testing, or neuropsychological testing.

21 The Department may order the examining physician or any
22 member of the multidisciplinary team to provide to the
23 Department any and all records, including business records,
24 that relate to the examination and evaluation, including any
25 supplemental testing performed.

26 The Department may order the examining physician or any

1 member of the multidisciplinary team to present testimony
2 concerning the mental or physical examination of the licensee
3 or applicant. No information, report, record, or other
4 documents in any way related to the examination shall be
5 excluded by reason of any common law or statutory privilege
6 relating to communications between the licensee or applicant
7 and the examining physician or any member of the
8 multidisciplinary team. No authorization is necessary from the
9 licensee or applicant ordered to undergo an examination for
10 the examining physician or any member of the multidisciplinary
11 team to provide information, reports, records, or other
12 documents or to provide any testimony regarding the
13 examination and evaluation.

14 The individual to be examined may have, at the
15 individual's own expense, another physician of the
16 individual's choice present during all aspects of this
17 examination. However, that physician shall be present only to
18 observe and may not interfere in any way with the examination.

19 Failure of an individual to submit to a mental or physical
20 examination, when ordered, shall result in an automatic
21 suspension of the individual's license until the individual
22 submits to the examination.

23 If the Department finds an individual unable to practice
24 because of the reasons set forth in this Section, the
25 Department may require that individual to submit to care,
26 counseling, or treatment by physicians approved or designated

1 by the Department, as a condition, term, or restriction for
2 continued, reinstated, or renewed licensure to practice; or,
3 in lieu of care, counseling, or treatment, the Department may
4 file a complaint to immediately suspend, revoke, or otherwise
5 discipline the license of the individual. An individual whose
6 license was granted, continued, reinstated, renewed,
7 disciplined, or supervised subject to such terms, conditions,
8 or restrictions, and who fails to comply with such terms,
9 conditions, or restrictions, shall be referred to the
10 Secretary for a determination whether the individual shall
11 have his or her license suspended immediately, pending a
12 hearing by the Department.

13 In instances in which the Department immediately suspends
14 a person's license under this Section, a hearing on that
15 person's license must be convened by the Department within 30
16 days after the suspension and completed without appreciable
17 delay. The Department shall have the authority to review the
18 subject individual's record of treatment and counseling
19 regarding the impairment to the extent permitted by applicable
20 federal statutes and regulations safeguarding the
21 confidentiality of medical records.

22 An individual licensed under this Act and affected under
23 this Section shall be afforded an opportunity to demonstrate
24 to the Department that the individual can resume practice in
25 compliance with acceptable and prevailing standards under the
26 provisions of the individual's license.

1 (e) An individual or organization acting in good faith,
2 and not in a willful and wanton manner, in complying with this
3 Section by providing a report or other information to the
4 Department, by assisting in the investigation or preparation
5 of a report or information, by participating in proceedings of
6 the Department, or by serving as a member of the Department,
7 shall not be subject to criminal prosecution or civil damages
8 as a result of such actions.

9 (f) Members of the Board and the Department shall be
10 indemnified by this State for any actions occurring within the
11 scope of services under the Act, done in good faith and not
12 willful and wanton in nature. The Attorney General shall
13 defend all such actions unless the Attorney General determines
14 either that there would be a conflict of interest in such
15 representation or that the actions complained of were not in
16 good faith or were willful and wanton.

17 If the Attorney General declines representation, the
18 member has the right to employ counsel of the member's choice,
19 whose fees shall be provided by this State, after approval by
20 the Attorney General, unless there is a determination by a
21 court that the member's actions were not in good faith or were
22 willful and wanton.

23 The member must notify the Attorney General within 7 days
24 after receipt of notice of the initiation of any action
25 involving services of the Board. Failure to notify the
26 Attorney General constitutes an absolute waiver of the right

1 to a defense and indemnification.

2 The Attorney General shall determine, within 7 days after
3 receiving such notice, whether the Attorney General will
4 undertake to represent the member.

5 Section 100. Investigation; notice; hearing. The
6 Department may investigate the actions of any applicant or of
7 any person or persons holding or claiming to hold a license.
8 The Department shall, before suspending, revoking, placing on
9 probationary status, or taking any other disciplinary action
10 as the Department may deem proper with regard to any license,
11 at least 30 days prior to the date set for the hearing, notify
12 the licensee in writing of any charges made and the time and
13 place for a hearing of the charges before the Department,
14 direct the licensee to file the licensee's written answer
15 thereto to the Department under oath within 20 days after the
16 service on the licensee of such notice and inform the licensee
17 that if the licensee fails to file such answer, default will be
18 taken against the licensee and the license may be suspended,
19 revoked, placed on probationary status, or have other
20 disciplinary action, including limiting the scope, nature or
21 extent of the licensee's practice, as the Department may deem
22 proper taken with regard thereto. Written or electronic notice
23 may be served by personal delivery, email, or mail to the
24 applicant or licensee at the licensee's address of record or
25 email address of record. At the time and place fixed in the

1 notice, the Department shall proceed to hear the charges and
2 the parties or their counsel shall be accorded ample
3 opportunity to present such statements, testimony, evidence,
4 and argument as may be pertinent to the charges or to the
5 defense thereto. The Department may continue such hearing from
6 time to time. In case the applicant or licensee, after
7 receiving notice, fails to file an answer, the licensee's
8 license may in the discretion of the Secretary, having
9 received first the recommendation of the Department, be
10 suspended, revoked, placed on probationary status, or the
11 Department may take whatever disciplinary action as the
12 Department may deem proper, including limiting the scope,
13 nature, or extent of such person's practice, without a
14 hearing, if the act or acts charged constitute sufficient
15 grounds for such action under this Act.

16 Section 105. Record of proceedings. The Department, at its
17 expense, shall preserve a record of all proceedings at the
18 formal hearing of any case involving the refusal to issue or
19 renew a license or discipline a licensee. The notice of
20 hearing, complaint, and all other documents in the nature of
21 pleadings and written motions filed in the proceedings, the
22 transcript of testimony, the report of the Department, and
23 orders of the Department shall be the record of such
24 proceeding.

1 Section 110. Confidentiality. All information collected by
2 the Department in the course of an examination or
3 investigation of a licensee or applicant, including, but not
4 limited to, any complaint against a licensee filed with the
5 Department and information collected to investigate any such
6 complaint, shall be maintained for the confidential use of the
7 Department and shall not be disclosed. The Department shall
8 not disclose the information to anyone other than law
9 enforcement officials, regulatory agencies that have an
10 appropriate regulatory interest as determined by the
11 Department, or a party presenting a lawful subpoena to the
12 Department. Information and documents disclosed to a federal,
13 State, county, or local law enforcement agency shall not be
14 disclosed by the agency for any purpose to any other agency or
15 person. A formal complaint filed against a licensee by the
16 Department or any order issued by the Department against a
17 licensee or applicant shall be a public record, except as
18 otherwise prohibited by law.

19 Section 115. Illinois Administrative Procedure Act. The
20 Illinois Administrative Procedure Act is expressly adopted and
21 incorporated herein as if all of the provisions of that Act
22 were included in this Act, except that the provision of
23 paragraph (d) of Section 10-65 of the Illinois Administrative
24 Procedure Act, which provides that at hearings the licensee or
25 person holding a license has the right to show compliance with

1 all lawful requirements for retention or continuation of the
2 license, is specifically excluded. For the purpose of this
3 Act, the notice required under Section 10-25 of the Illinois
4 Administrative Procedure Act is deemed sufficient when
5 personally served, mailed to the address of record of the
6 applicant or licensee, or emailed to the email address of
7 record of the applicant or licensee.

8 Section 116. The Medical Practice Act of 1987 is amended
9 by changing Section 54.5 as follows:

10 (225 ILCS 60/54.5)

11 (Section scheduled to be repealed on January 1, 2027)

12 Sec. 54.5. Physician delegation of authority to physician
13 assistants, advanced practice registered nurses without full
14 practice authority, ~~and~~ prescribing psychologists, and
15 naturopathic doctors without full practice authority.

16 (a) Physicians licensed to practice medicine in all its
17 branches may delegate care and treatment responsibilities to a
18 physician assistant under guidelines in accordance with the
19 requirements of the Physician Assistant Practice Act of 1987.
20 A physician licensed to practice medicine in all its branches
21 may enter into collaborative agreements with no more than 7
22 full-time equivalent physician assistants, except in a
23 hospital, hospital affiliate, or ambulatory surgical treatment
24 center as set forth by Section 7.7 of the Physician Assistant

1 Practice Act of 1987 and as provided in subsection (a-5).

2 (a-5) A physician licensed to practice medicine in all its
3 branches may collaborate with more than 7 physician assistants
4 when the services are provided in a federal primary care
5 health professional shortage area with a Health Professional
6 Shortage Area score greater than or equal to 12, as determined
7 by the United States Department of Health and Human Services.

8 The collaborating physician must keep appropriate
9 documentation of meeting this exemption and make it available
10 to the Department upon request.

11 (b) A physician licensed to practice medicine in all its
12 branches in active clinical practice may collaborate with an
13 advanced practice registered nurse in accordance with the
14 requirements of the Nurse Practice Act. Collaboration is for
15 the purpose of providing medical consultation, and no
16 employment relationship is required. A written collaborative
17 agreement shall conform to the requirements of Section 65-35
18 of the Nurse Practice Act. The written collaborative agreement
19 shall be for services for which the collaborating physician
20 can provide adequate collaboration. A written collaborative
21 agreement shall be adequate with respect to collaboration with
22 advanced practice registered nurses if all of the following
23 apply:

24 (1) The agreement is written to promote the exercise
25 of professional judgment by the advanced practice
26 registered nurse commensurate with his or her education

1 and experience.

2 (2) The advanced practice registered nurse provides
3 services based upon a written collaborative agreement with
4 the collaborating physician, except as set forth in
5 subsection (b-5) of this Section. With respect to labor
6 and delivery, the collaborating physician must provide
7 delivery services in order to participate with a certified
8 nurse midwife.

9 (3) Methods of communication are available with the
10 collaborating physician in person or through
11 telecommunications for consultation, collaboration, and
12 referral as needed to address patient care needs.

13 (b-5) An anesthesiologist or physician licensed to
14 practice medicine in all its branches may collaborate with a
15 certified registered nurse anesthetist in accordance with
16 Section 65-35 of the Nurse Practice Act for the provision of
17 anesthesia services. With respect to the provision of
18 anesthesia services, the collaborating anesthesiologist or
19 physician shall have training and experience in the delivery
20 of anesthesia services consistent with Department rules.
21 Collaboration shall be adequate if:

22 (1) an anesthesiologist or a physician participates in
23 the joint formulation and joint approval of orders or
24 guidelines and periodically reviews such orders and the
25 services provided patients under such orders; and

26 (2) for anesthesia services, the anesthesiologist or

1 physician participates through discussion of and agreement
2 with the anesthesia plan and is physically present and
3 available on the premises during the delivery of
4 anesthesia services for diagnosis, consultation, and
5 treatment of emergency medical conditions. Anesthesia
6 services in a hospital shall be conducted in accordance
7 with Section 10.7 of the Hospital Licensing Act and in an
8 ambulatory surgical treatment center in accordance with
9 Section 6.5 of the Ambulatory Surgical Treatment Center
10 Act.

11 (b-10) The anesthesiologist or operating physician must
12 agree with the anesthesia plan prior to the delivery of
13 services.

14 (c) A physician licensed to practice medicine in all its
15 branches in active clinical practice may collaborate with a
16 naturopathic doctor in accordance with the requirements of the
17 Naturopathic Medical Practice Act. Collaboration shall be for
18 the purpose of providing medical consultation and an
19 employment relationship shall not be required. A written
20 collaborative agreement shall conform to the requirements of
21 Section 30 of the Naturopathic Medical Practice Act. The
22 written collaborative agreement shall be for services for
23 which the collaborating physician can provide adequate
24 collaboration. A written collaborative agreement shall be
25 adequate with respect to collaboration with naturopathic
26 doctors if all of the following apply:

1 (1) The agreement is written to promote the exercise
2 of professional judgment by the naturopathic doctor
3 commensurate with his or her education and experience.

4 (2) The naturopathic doctor provides services based
5 upon a written collaborative agreement with the
6 collaborating physician.

7 (3) Methods of communication with the collaborating
8 physician are available in person or through
9 telecommunications for consultation, collaboration, and
10 referral as needed to address patient care needs.

11 (d) ~~(e)~~ The collaborating physician shall have access to
12 the medical records of all patients attended to by a physician
13 assistant. The collaborating physician shall have access to
14 the medical records of all patients attended to by an advanced
15 practice registered nurse. The collaborating physician shall
16 have access to the medical records of all patients attended to
17 by a naturopathic doctor.

18 ~~(d) (Blank).~~

19 (e) A physician shall not be liable for the acts or
20 omissions of a prescribing psychologist, physician assistant,
21 ~~or~~ advanced practice registered nurse, or naturopathic doctor
22 solely on the basis of having signed a supervision agreement
23 or guidelines or a collaborative agreement, an order, a
24 standing medical order, a standing delegation order, or other
25 order or guideline authorizing a prescribing psychologist,
26 physician assistant, ~~or~~ advanced practice registered nurse, or

1 naturopathic doctor to perform acts, unless the physician has
2 reason to believe the prescribing psychologist, physician
3 assistant, ~~or~~ advanced practice registered nurse, or
4 naturopathic doctor lacked the competency to perform the act
5 or acts or commits willful and wanton misconduct.

6 (f) A collaborating physician may, but is not required to,
7 delegate prescriptive authority to an advanced practice
8 registered nurse as part of a written collaborative agreement,
9 and the delegation of prescriptive authority shall conform to
10 the requirements of Section 65-40 of the Nurse Practice Act.

11 (g) A collaborating physician may, but is not required to,
12 delegate prescriptive authority to a physician assistant as
13 part of a written collaborative agreement, and the delegation
14 of prescriptive authority shall conform to the requirements of
15 Section 7.5 of the Physician Assistant Practice Act of 1987.

16 (h) (Blank).

17 (i) A collaborating physician shall delegate prescriptive
18 authority to a prescribing psychologist as part of a written
19 collaborative agreement, and the delegation of prescriptive
20 authority shall conform to the requirements of Section 4.3 of
21 the Clinical Psychologist Licensing Act.

22 (j) As set forth in Section 22.2 of this Act, a licensee
23 under this Act may not directly or indirectly divide, share,
24 or split any professional fee or other form of compensation
25 for professional services with anyone in exchange for a
26 referral or otherwise, other than as provided in Section 22.2.

1 (k) A collaborating physician may, but is not required to,
2 delegate prescriptive authority to a naturopathic doctor as
3 part of a written collaborative agreement, and the delegation
4 of prescriptive authority shall conform to the requirements of
5 Section 30 of the Naturopathic Medical Practice Act.

6 (Source: P.A. 103-228, eff. 1-1-24.)

7 Section 120. The Illinois Controlled Substances Act is
8 amended by changing Section 102 as follows:

9 (720 ILCS 570/102) (from Ch. 56 1/2, par. 1102)

10 Sec. 102. Definitions. As used in this Act, unless the
11 context otherwise requires:

12 (a) "Person with a substance use disorder" means any
13 person who has a substance use disorder diagnosis defined as a
14 spectrum of persistent and recurring problematic behavior that
15 encompasses 10 separate classes of drugs: alcohol; caffeine;
16 cannabis; hallucinogens; inhalants; opioids; sedatives,
17 hypnotics and anxiolytics; stimulants; and tobacco; and other
18 unknown substances leading to clinically significant
19 impairment or distress.

20 (b) "Administer" means the direct application of a
21 controlled substance, whether by injection, inhalation,
22 ingestion, or any other means, to the body of a patient,
23 research subject, or animal (as defined by the Humane
24 Euthanasia in Animal Shelters Act) by:

1 (1) a practitioner (or, in his or her presence, by his
2 or her authorized agent),

3 (2) the patient or research subject pursuant to an
4 order, or

5 (3) a euthanasia technician as defined by the Humane
6 Euthanasia in Animal Shelters Act.

7 (c) "Agent" means an authorized person who acts on behalf
8 of or at the direction of a manufacturer, distributor,
9 dispenser, prescriber, or practitioner. It does not include a
10 common or contract carrier, public warehouseman or employee of
11 the carrier or warehouseman.

12 (c-1) "Anabolic Steroids" means any drug or hormonal
13 substance, chemically and pharmacologically related to
14 testosterone (other than estrogens, progestins,
15 corticosteroids, and dehydroepiandrosterone), and includes:

16 (i) 3[beta],17-dihydroxy-5a-androstane,

17 (ii) 3[alpha],17[beta]-dihydroxy-5a-androstane,

18 (iii) 5[alpha]-androstan-3,17-dione,

19 (iv) 1-androstenediol (3[beta],

20 17[beta]-dihydroxy-5[alpha]-androst-1-ene),

21 (v) 1-androstenediol (3[alpha],

22 17[beta]-dihydroxy-5[alpha]-androst-1-ene),

23 (vi) 4-androstenediol

24 (3[beta],17[beta]-dihydroxy-androst-4-ene),

25 (vii) 5-androstenediol

26 (3[beta],17[beta]-dihydroxy-androst-5-ene),

(viii) 1-androstenedione
([5alpha]-androst-1-en-3,17-dione),
(ix) 4-androstenedione
(androst-4-en-3,17-dione),
(x) 5-androstenedione
(androst-5-en-3,17-dione),
(xi) bolasterone (7[alpha],17a-dimethyl-17[beta]-
hydroxyandrost-4-en-3-one),
(xii) boldenone (17[beta]-hydroxyandrost-
1,4,-diene-3-one),
(xiii) boldione (androsta-1,4-
diene-3,17-dione),
(xiv) calusterone (7[beta],17[alpha]-dimethyl-17
[beta]-hydroxyandrost-4-en-3-one),
(xv) clostebol (4-chloro-17[beta]-
hydroxyandrost-4-en-3-one),
(xvi) dehydrochloromethyltestosterone (4-chloro-
17[beta]-hydroxy-17[alpha]-methyl-
androst-1,4-dien-3-one),
(xvii) desoxymethyltestosterone
(17[alpha]-methyl-5[alpha]
-androst-2-en-17[beta]-ol) (a.k.a., madol),
(xviii) [delta]1-dihydrotestosterone (a.k.a.
'1-testosterone') (17[beta]-hydroxy-
5[alpha]-androst-1-en-3-one),
(xix) 4-dihydrotestosterone (17[beta]-hydroxy-

1 androstan-3-one),
2 (xx) drostanolone (17[beta]-hydroxy-2[alpha]-methyl-
3 5[alpha]-androstan-3-one),
4 (xxi) ethylestrenol (17[alpha]-ethyl-17[beta]-
5 hydroxyestr-4-ene),
6 (xxii) fluoxymesterone (9-fluoro-17[alpha]-methyl-
7 1[beta],17[beta]-dihydroxyandrost-4-en-3-one),
8 (xxiii) formebolone (2-formyl-17[alpha]-methyl-11[alpha],
9 17[beta]-dihydroxyandrost-1,4-dien-3-one),
10 (xxiv) furazabol (17[alpha]-methyl-17[beta]-
11 hydroxyandrostano[2,3-c]-furazan),
12 (xxv) 13[beta]-ethyl-17[beta]-hydroxygon-4-en-3-one,
13 (xxvi) 4-hydroxytestosterone (4,17[beta]-dihydroxy-
14 androst-4-en-3-one),
15 (xxvii) 4-hydroxy-19-nortestosterone (4,17[beta]-
16 dihydroxy-estr-4-en-3-one),
17 (xxviii) mestanolone (17[alpha]-methyl-17[beta]-
18 hydroxy-5-androstan-3-one),
19 (xxix) mesterolone (1-methyl-17[beta]-hydroxy-
20 [5a]-androstan-3-one),
21 (xxx) methandienone (17[alpha]-methyl-17[beta]-
22 hydroxyandrost-1,4-dien-3-one),
23 (xxxi) methandriol (17[alpha]-methyl-3[beta],17[beta]-
24 dihydroxyandrost-5-ene),
25 (xxxii) methenolone (1-methyl-17[beta]-hydroxy-
26 5[alpha]-androst-1-en-3-one),

(xxxiii) 17[alpha]-methyl-3[beta], 17[beta]-
dihydroxy-5a-androstane,
(xxxiv) 17[alpha]-methyl-3[alpha],17[beta]-dihydroxy
-5a-androstane,
(xxxv) 17[alpha]-methyl-3[beta],17[beta]-
dihydroxyandrost-4-ene),
(xxxvi) 17[alpha]-methyl-4-hydroxynandrolone (17[alpha]-
methyl-4-hydroxy-17[beta]-hydroxyestr-4-en-3-one),
(xxxvii) methyldienolone (17[alpha]-methyl-17[beta]-
hydroxyestra-4,9(10)-dien-3-one),
(xxxviii) methyltrienolone (17[alpha]-methyl-17[beta]-
hydroxyestra-4,9-11-trien-3-one),
(xxxix) methyltestosterone (17[alpha]-methyl-17[beta]-
hydroxyandrost-4-en-3-one),
(xl) mibolerone (7[alpha],17a-dimethyl-17[beta]-
hydroxyestr-4-en-3-one),
(xli) 17[alpha]-methyl-[delta]1-dihydrotestosterone
(17b[beta]-hydroxy-17[alpha]-methyl-5[alpha]-
androst-1-en-3-one) (a.k.a. '17-[alpha]-methyl-
1-testosterone'),
(xlii) nandrolone (17[beta]-hydroxyestr-4-en-3-one),
(xliii) 19-nor-4-androstenediol (3[beta], 17[beta]-
dihydroxyestr-4-ene),
(xliv) 19-nor-4-androstenediol (3[alpha], 17[beta]-
dihydroxyestr-4-ene),
(xlv) 19-nor-5-androstenediol (3[beta], 17[beta]-

1 dihydroxyestr-5-ene),
2 (xlvi) 19-nor-5-androstenediol (3[alpha], 17[beta]-
3 dihydroxyestr-5-ene),
4 (xlvii) 19-nor-4,9(10)-androstadienedione
5 (estra-4,9(10)-diene-3,17-dione),
6 (xlviii) 19-nor-4-androstenedione (estr-4-
7 en-3,17-dione),
8 (xlix) 19-nor-5-androstenedione (estr-5-
9 en-3,17-dione),
10 (l) norbolethone (13[beta], 17a-diethyl-17[beta]-
11 hydroxygon-4-en-3-one),
12 (li) norclostebol (4-chloro-17[beta]-
13 hydroxyestr-4-en-3-one),
14 (lii) norethandrolone (17[alpha]-ethyl-17[beta]-
15 hydroxyestr-4-en-3-one),
16 (liii) normethandrolone (17[alpha]-methyl-17[beta]-
17 hydroxyestr-4-en-3-one),
18 (liv) oxandrolone (17[alpha]-methyl-17[beta]-hydroxy-
19 2-oxa-5[alpha]-androstan-3-one),
20 (lv) oxymesterone (17[alpha]-methyl-4,17[beta]-
21 dihydroxyandrost-4-en-3-one),
22 (lvi) oxymetholone (17[alpha]-methyl-2-hydroxymethylene-
23 17[beta]-hydroxy-(5[alpha]-androstan-3-one),
24 (lvii) stanozolol (17[alpha]-methyl-17[beta]-hydroxy-
25 (5[alpha]-androst-2-eno[3,2-c]-pyrazole),
26 (lviii) stenbolone (17[beta]-hydroxy-2-methyl-

1 (5[alpha]-androst-1-en-3-one),
2 (lix) testolactone (13-hydroxy-3-oxo-13,17-
3 secoandrosta-1,4-dien-17-oic
4 acid lactone),
5 (lx) testosterone (17[beta]-hydroxyandrost-
6 4-en-3-one),
7 (lxi) tetrahydrogestrinone (13[beta], 17[alpha]-
8 diethyl-17[beta]-hydroxygon-
9 4,9,11-trien-3-one),
10 (lxii) trenbolone (17[beta]-hydroxyestr-4,9,
11 11-trien-3-one).

12 Any person who is otherwise lawfully in possession of an
13 anabolic steroid, or who otherwise lawfully manufactures,
14 distributes, dispenses, delivers, or possesses with intent to
15 deliver an anabolic steroid, which anabolic steroid is
16 expressly intended for and lawfully allowed to be administered
17 through implants to livestock or other nonhuman species, and
18 which is approved by the Secretary of Health and Human
19 Services for such administration, and which the person intends
20 to administer or have administered through such implants,
21 shall not be considered to be in unauthorized possession or to
22 unlawfully manufacture, distribute, dispense, deliver, or
23 possess with intent to deliver such anabolic steroid for
24 purposes of this Act.

25 (d) "Administration" means the Drug Enforcement
26 Administration, United States Department of Justice, or its

1 successor agency.

2 (d-5) "Clinical Director, Prescription Monitoring Program"
3 means a Department of Human Services administrative employee
4 licensed to either prescribe or dispense controlled substances
5 who shall run the clinical aspects of the Department of Human
6 Services Prescription Monitoring Program and its Prescription
7 Information Library.

8 (d-10) "Compounding" means the preparation and mixing of
9 components, excluding flavorings, (1) as the result of a
10 prescriber's prescription drug order or initiative based on
11 the prescriber-patient-pharmacist relationship in the course
12 of professional practice or (2) for the purpose of, or
13 incident to, research, teaching, or chemical analysis and not
14 for sale or dispensing. "Compounding" includes the preparation
15 of drugs or devices in anticipation of receiving prescription
16 drug orders based on routine, regularly observed dispensing
17 patterns. Commercially available products may be compounded
18 for dispensing to individual patients only if both of the
19 following conditions are met: (i) the commercial product is
20 not reasonably available from normal distribution channels in
21 a timely manner to meet the patient's needs and (ii) the
22 prescribing practitioner has requested that the drug be
23 compounded.

24 (e) "Control" means to add a drug or other substance, or
25 immediate precursor, to a Schedule whether by transfer from
26 another Schedule or otherwise.

1 (f) "Controlled Substance" means (i) a drug, substance,
2 immediate precursor, or synthetic drug in the Schedules of
3 Article II of this Act or (ii) a drug or other substance, or
4 immediate precursor, designated as a controlled substance by
5 the Department through administrative rule. The term does not
6 include distilled spirits, wine, malt beverages, or tobacco,
7 as those terms are defined or used in the Liquor Control Act of
8 1934 and the Tobacco Products Tax Act of 1995.

9 (f-5) "Controlled substance analog" means a substance:

10 (1) the chemical structure of which is substantially
11 similar to the chemical structure of a controlled
12 substance in Schedule I or II;

13 (2) which has a stimulant, depressant, or
14 hallucinogenic effect on the central nervous system that
15 is substantially similar to or greater than the stimulant,
16 depressant, or hallucinogenic effect on the central
17 nervous system of a controlled substance in Schedule I or
18 II; or

19 (3) with respect to a particular person, which such
20 person represents or intends to have a stimulant,
21 depressant, or hallucinogenic effect on the central
22 nervous system that is substantially similar to or greater
23 than the stimulant, depressant, or hallucinogenic effect
24 on the central nervous system of a controlled substance in
25 Schedule I or II.

26 (g) "Counterfeit substance" means a controlled substance,

1 which, or the container or labeling of which, without
2 authorization bears the trademark, trade name, or other
3 identifying mark, imprint, number or device, or any likeness
4 thereof, of a manufacturer, distributor, or dispenser other
5 than the person who in fact manufactured, distributed, or
6 dispensed the substance.

7 (h) "Deliver" or "delivery" means the actual, constructive
8 or attempted transfer of possession of a controlled substance,
9 with or without consideration, whether or not there is an
10 agency relationship. "Deliver" or "delivery" does not include
11 the donation of drugs to the extent permitted under the
12 Illinois Drug Reuse Opportunity Program Act.

13 (i) "Department" means the Illinois Department of Human
14 Services (as successor to the Department of Alcoholism and
15 Substance Abuse) or its successor agency.

16 (j) (Blank).

17 (k) "Department of Corrections" means the Department of
18 Corrections of the State of Illinois or its successor agency.

19 (l) "Department of Financial and Professional Regulation"
20 means the Department of Financial and Professional Regulation
21 of the State of Illinois or its successor agency.

22 (m) "Depressant" means any drug that (i) causes an overall
23 depression of central nervous system functions, (ii) causes
24 impaired consciousness and awareness, and (iii) can be
25 habit-forming or lead to a substance misuse or substance use
26 disorder, including, but not limited to, alcohol, cannabis and

1 its active principles and their analogs, benzodiazepines and
2 their analogs, barbiturates and their analogs, opioids
3 (natural and synthetic) and their analogs, and chloral hydrate
4 and similar sedative hypnotics.

5 (n) (Blank).

6 (o) "Director" means the Director of the Illinois State
7 Police or his or her designated agents.

8 (p) "Dispense" means to deliver a controlled substance to
9 an ultimate user or research subject by or pursuant to the
10 lawful order of a prescriber, including the prescribing,
11 administering, packaging, labeling, or compounding necessary
12 to prepare the substance for that delivery.

13 (q) "Dispenser" means a practitioner who dispenses.

14 (r) "Distribute" means to deliver, other than by
15 administering or dispensing, a controlled substance.

16 (s) "Distributor" means a person who distributes.

17 (t) "Drug" means (1) substances recognized as drugs in the
18 official United States Pharmacopoeia, Official Homeopathic
19 Pharmacopoeia of the United States, or official National
20 Formulary, or any supplement to any of them; (2) substances
21 intended for use in diagnosis, cure, mitigation, treatment, or
22 prevention of disease in man or animals; (3) substances (other
23 than food) intended to affect the structure of any function of
24 the body of man or animals and (4) substances intended for use
25 as a component of any article specified in clause (1), (2), or
26 (3) of this subsection. It does not include devices or their

1 components, parts, or accessories.

2 (t-3) "Electronic health record" or "EHR" means an
3 electronic record of health-related information on an
4 individual that is created, gathered, managed, and consulted
5 by authorized health care clinicians and staff.

6 (t-3.5) "Electronic health record system" or "EHR system"
7 means any computer-based system or combination of federally
8 certified Health IT Modules (defined at 42 CFR 170.102 or its
9 successor) used as a repository for electronic health records
10 and accessed or updated by a prescriber or authorized
11 surrogate in the ordinary course of his or her medical
12 practice. For purposes of connecting to the Prescription
13 Information Library maintained by the Bureau of Pharmacy and
14 Clinical Support Systems or its successor, an EHR system may
15 connect to the Prescription Information Library directly or
16 through all or part of a computer program or system that is a
17 federally certified Health IT Module maintained by a third
18 party and used by the EHR system to secure access to the
19 database.

20 (t-4) "Emergency medical services personnel" has the
21 meaning ascribed to it in the Emergency Medical Services (EMS)
22 Systems Act.

23 (t-5) "Euthanasia agency" means an entity certified by the
24 Department of Financial and Professional Regulation for the
25 purpose of animal euthanasia that holds an animal control
26 facility license or animal shelter license under the Animal

1 Welfare Act. A euthanasia agency is authorized to purchase,
2 store, possess, and utilize Schedule II nonnarcotic and
3 Schedule III nonnarcotic drugs for the sole purpose of animal
4 euthanasia.

5 (t-10) "Euthanasia drugs" means Schedule II or Schedule
6 III substances (nonnarcotic controlled substances) that are
7 used by a euthanasia agency for the purpose of animal
8 euthanasia.

9 (u) "Good faith" means the prescribing or dispensing of a
10 controlled substance by a practitioner in the regular course
11 of professional treatment to or for any person who is under his
12 or her treatment for a pathology or condition other than that
13 individual's physical or psychological dependence upon a
14 controlled substance, except as provided herein: and
15 application of the term to a pharmacist shall mean the
16 dispensing of a controlled substance pursuant to the
17 prescriber's order which in the professional judgment of the
18 pharmacist is lawful. The pharmacist shall be guided by
19 accepted professional standards, including, but not limited
20 to, the following, in making the judgment:

21 (1) lack of consistency of prescriber-patient
22 relationship,

23 (2) frequency of prescriptions for same drug by one
24 prescriber for large numbers of patients,

25 (3) quantities beyond those normally prescribed,

26 (4) unusual dosages (recognizing that there may be

1 clinical circumstances where more or less than the usual
2 dose may be used legitimately),

3 (5) unusual geographic distances between patient,
4 pharmacist and prescriber,

5 (6) consistent prescribing of habit-forming drugs.

6 (u-0.5) "Hallucinogen" means a drug that causes markedly
7 altered sensory perception leading to hallucinations of any
8 type.

9 (u-1) "Home infusion services" means services provided by
10 a pharmacy in compounding solutions for direct administration
11 to a patient in a private residence, long-term care facility,
12 or hospice setting by means of parenteral, intravenous,
13 intramuscular, subcutaneous, or intraspinal infusion.

14 (u-5) "Illinois State Police" means the Illinois State
15 Police or its successor agency.

16 (v) "Immediate precursor" means a substance:

17 (1) which the Department has found to be and by rule
18 designated as being a principal compound used, or produced
19 primarily for use, in the manufacture of a controlled
20 substance;

21 (2) which is an immediate chemical intermediary used
22 or likely to be used in the manufacture of such controlled
23 substance; and

24 (3) the control of which is necessary to prevent,
25 curtail or limit the manufacture of such controlled
26 substance.

1 (w) "Instructional activities" means the acts of teaching,
2 educating or instructing by practitioners using controlled
3 substances within educational facilities approved by the State
4 Board of Education or its successor agency.

5 (x) "Local authorities" means a duly organized State,
6 County or Municipal peace unit or police force.

7 (y) "Look-alike substance" means a substance, other than a
8 controlled substance which (1) by overall dosage unit
9 appearance, including shape, color, size, markings or lack
10 thereof, taste, consistency, or any other identifying physical
11 characteristic of the substance, would lead a reasonable
12 person to believe that the substance is a controlled
13 substance, or (2) is expressly or impliedly represented to be
14 a controlled substance or is distributed under circumstances
15 which would lead a reasonable person to believe that the
16 substance is a controlled substance. For the purpose of
17 determining whether the representations made or the
18 circumstances of the distribution would lead a reasonable
19 person to believe the substance to be a controlled substance
20 under this clause (2) of subsection (y), the court or other
21 authority may consider the following factors in addition to
22 any other factor that may be relevant:

23 (a) statements made by the owner or person in control
24 of the substance concerning its nature, use or effect;

25 (b) statements made to the buyer or recipient that the
26 substance may be resold for profit;

1 (c) whether the substance is packaged in a manner
2 normally used for the illegal distribution of controlled
3 substances;

4 (d) whether the distribution or attempted distribution
5 included an exchange of or demand for money or other
6 property as consideration, and whether the amount of the
7 consideration was substantially greater than the
8 reasonable retail market value of the substance.

9 Clause (1) of this subsection (y) shall not apply to a
10 noncontrolled substance in its finished dosage form that was
11 initially introduced into commerce prior to the initial
12 introduction into commerce of a controlled substance in its
13 finished dosage form which it may substantially resemble.

14 Nothing in this subsection (y) prohibits the dispensing or
15 distributing of noncontrolled substances by persons authorized
16 to dispense and distribute controlled substances under this
17 Act, provided that such action would be deemed to be carried
18 out in good faith under subsection (u) if the substances
19 involved were controlled substances.

20 Nothing in this subsection (y) or in this Act prohibits
21 the manufacture, preparation, propagation, compounding,
22 processing, packaging, advertising or distribution of a drug
23 or drugs by any person registered pursuant to Section 510 of
24 the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360).

25 (y-1) "Mail-order pharmacy" means a pharmacy that is
26 located in a state of the United States that delivers,

1 dispenses or distributes, through the United States Postal
2 Service or other common carrier, to Illinois residents, any
3 substance which requires a prescription.

4 (z) "Manufacture" means the production, preparation,
5 propagation, compounding, conversion or processing of a
6 controlled substance other than methamphetamine, either
7 directly or indirectly, by extraction from substances of
8 natural origin, or independently by means of chemical
9 synthesis, or by a combination of extraction and chemical
10 synthesis, and includes any packaging or repackaging of the
11 substance or labeling of its container, except that this term
12 does not include:

13 (1) by an ultimate user, the preparation or
14 compounding of a controlled substance for his or her own
15 use;

16 (2) by a practitioner, or his or her authorized agent
17 under his or her supervision, the preparation,
18 compounding, packaging, or labeling of a controlled
19 substance:

20 (a) as an incident to his or her administering or
21 dispensing of a controlled substance in the course of
22 his or her professional practice; or

23 (b) as an incident to lawful research, teaching or
24 chemical analysis and not for sale; or

25 (3) the packaging, repackaging, or labeling of drugs
26 only to the extent permitted under the Illinois Drug Reuse

1 Opportunity Program Act.

2 (z-1) (Blank).

3 (z-5) "Medication shopping" means the conduct prohibited
4 under subsection (a) of Section 314.5 of this Act.

5 (z-10) "Mid-level practitioner" means (i) a physician
6 assistant who has been delegated authority to prescribe
7 through a written delegation of authority by a physician
8 licensed to practice medicine in all of its branches, in
9 accordance with Section 7.5 of the Physician Assistant
10 Practice Act of 1987, (ii) an advanced practice registered
11 nurse who has been delegated authority to prescribe through a
12 written delegation of authority by a physician licensed to
13 practice medicine in all of its branches or by a podiatric
14 physician, in accordance with Section 65-40 of the Nurse
15 Practice Act, (iii) an advanced practice registered nurse
16 certified as a nurse practitioner, nurse midwife, or clinical
17 nurse specialist who has been granted authority to prescribe
18 by a hospital affiliate in accordance with Section 65-45 of
19 the Nurse Practice Act, (iv) an animal euthanasia agency, or
20 (v) a prescribing psychologist.

21 (aa) "Narcotic drug" means any of the following, whether
22 produced directly or indirectly by extraction from substances
23 of vegetable origin, or independently by means of chemical
24 synthesis, or by a combination of extraction and chemical
25 synthesis:

26 (1) opium, opiates, derivatives of opium and opiates,

1 including their isomers, esters, ethers, salts, and salts
2 of isomers, esters, and ethers, whenever the existence of
3 such isomers, esters, ethers, and salts is possible within
4 the specific chemical designation; however the term
5 "narcotic drug" does not include the isoquinoline
6 alkaloids of opium;

7 (2) (blank);

8 (3) opium poppy and poppy straw;

9 (4) coca leaves, except coca leaves and extracts of
10 coca leaves from which substantially all of the cocaine
11 and ecgonine, and their isomers, derivatives and salts,
12 have been removed;

13 (5) cocaine, its salts, optical and geometric isomers,
14 and salts of isomers;

15 (6) ecgonine, its derivatives, their salts, isomers,
16 and salts of isomers;

17 (7) any compound, mixture, or preparation which
18 contains any quantity of any of the substances referred to
19 in subparagraphs (1) through (6).

20 (bb) "Nurse" means a registered nurse licensed under the
21 Nurse Practice Act.

22 (cc) (Blank).

23 (dd) "Opiate" means a drug derived from or related to
24 opium.

25 (ee) "Opium poppy" means the plant of the species *Papaver*
26 *somniferum* L., except its seeds.

1 (ee-5) "Oral dosage" means a tablet, capsule, elixir, or
2 solution or other liquid form of medication intended for
3 administration by mouth, but the term does not include a form
4 of medication intended for buccal, sublingual, or transmucosal
5 administration.

6 (ff) "Parole and Pardon Board" means the Parole and Pardon
7 Board of the State of Illinois or its successor agency.

8 (gg) "Person" means any individual, corporation,
9 mail-order pharmacy, government or governmental subdivision or
10 agency, business trust, estate, trust, partnership or
11 association, or any other entity.

12 (hh) "Pharmacist" means any person who holds a license or
13 certificate of registration as a registered pharmacist, a
14 local registered pharmacist or a registered assistant
15 pharmacist under the Pharmacy Practice Act.

16 (ii) "Pharmacy" means any store, ship or other place in
17 which pharmacy is authorized to be practiced under the
18 Pharmacy Practice Act.

19 (ii-5) "Pharmacy shopping" means the conduct prohibited
20 under subsection (b) of Section 314.5 of this Act.

21 (ii-10) "Physician" (except when the context otherwise
22 requires) means a person licensed to practice medicine in all
23 of its branches.

24 (jj) "Poppy straw" means all parts, except the seeds, of
25 the opium poppy, after mowing.

26 (kk) "Practitioner" means a physician licensed to practice

1 medicine in all its branches, dentist, optometrist, podiatric
2 physician, veterinarian, scientific investigator, pharmacist,
3 physician assistant, advanced practice registered nurse,
4 licensed practical nurse, registered nurse, emergency medical
5 services personnel, hospital, laboratory, or pharmacy, or
6 other person licensed, registered, or otherwise lawfully
7 permitted by the United States or this State to distribute,
8 dispense, conduct research with respect to, administer or use
9 in teaching or chemical analysis, a controlled substance in
10 the course of professional practice or research.

11 (ll) "Pre-printed prescription" means a written
12 prescription upon which the designated drug has been indicated
13 prior to the time of issuance; the term does not mean a written
14 prescription that is individually generated by machine or
15 computer in the prescriber's office.

16 (mm) "Prescriber" means a physician licensed to practice
17 medicine in all its branches, dentist, optometrist,
18 prescribing psychologist licensed under Section 4.2 of the
19 Clinical Psychologist Licensing Act with prescriptive
20 authority delegated under Section 4.3 of the Clinical
21 Psychologist Licensing Act, podiatric physician, or
22 veterinarian who issues a prescription, a physician assistant
23 who issues a prescription for a controlled substance in
24 accordance with Section 303.05, a written delegation, and a
25 written collaborative agreement required under Section 7.5 of
26 the Physician Assistant Practice Act of 1987, an advanced

1 practice registered nurse with prescriptive authority
2 delegated under Section 65-40 of the Nurse Practice Act and in
3 accordance with Section 303.05, a written delegation, and a
4 written collaborative agreement under Section 65-35 of the
5 Nurse Practice Act, an advanced practice registered nurse
6 certified as a nurse practitioner, nurse midwife, or clinical
7 nurse specialist who has been granted authority to prescribe
8 by a hospital affiliate in accordance with Section 65-45 of
9 the Nurse Practice Act and in accordance with Section 303.05,
10 ~~or~~ an advanced practice registered nurse certified as a nurse
11 practitioner, nurse midwife, or clinical nurse specialist who
12 has full practice authority pursuant to Section 65-43 of the
13 Nurse Practice Act, or a naturopathic doctor with prescriptive
14 authority delegated under Section 30 of the Naturopathic
15 Medical Practice Act or who has full practice authority
16 pursuant to Section 40 or Section 45 of the Naturopathic
17 Medical Practice Act.

18 (nn) "Prescription" means a written, facsimile, or oral
19 order, or an electronic order that complies with applicable
20 federal requirements, of a physician licensed to practice
21 medicine in all its branches, dentist, podiatric physician or
22 veterinarian for any controlled substance, of an optometrist
23 in accordance with Section 15.1 of the Illinois Optometric
24 Practice Act of 1987, of a prescribing psychologist licensed
25 under Section 4.2 of the Clinical Psychologist Licensing Act
26 with prescriptive authority delegated under Section 4.3 of the

1 Clinical Psychologist Licensing Act, of a physician assistant
2 for a controlled substance in accordance with Section 303.05,
3 a written delegation, and a written collaborative agreement
4 required under Section 7.5 of the Physician Assistant Practice
5 Act of 1987, of an advanced practice registered nurse with
6 prescriptive authority delegated under Section 65-40 of the
7 Nurse Practice Act who issues a prescription for a controlled
8 substance in accordance with Section 303.05, a written
9 delegation, and a written collaborative agreement under
10 Section 65-35 of the Nurse Practice Act, of an advanced
11 practice registered nurse certified as a nurse practitioner,
12 nurse midwife, or clinical nurse specialist who has been
13 granted authority to prescribe by a hospital affiliate in
14 accordance with Section 65-45 of the Nurse Practice Act and in
15 accordance with Section 303.05 when required by law, ~~or~~ of an
16 advanced practice registered nurse certified as a nurse
17 practitioner, nurse midwife, or clinical nurse specialist who
18 has full practice authority pursuant to Section 65-43 of the
19 Nurse Practice Act, or of a naturopathic doctor with
20 prescriptive authority delegated under Section 30 of the
21 Naturopathic Medical Practice Act or who has full practice
22 authority pursuant to Section 40 or Section 45 of the
23 Naturopathic Medical Practice Act.

24 (nn-5) "Prescription Information Library" (PIL) means an
25 electronic library that contains reported controlled substance
26 data.

1 (nn-10) "Prescription Monitoring Program" (PMP) means the
2 entity that collects, tracks, and stores reported data on
3 controlled substances and select drugs pursuant to Section
4 316.

5 (oo) "Production" or "produce" means manufacture,
6 planting, cultivating, growing, or harvesting of a controlled
7 substance other than methamphetamine.

8 (pp) "Registrant" means every person who is required to
9 register under Section 302 of this Act.

10 (qq) "Registry number" means the number assigned to each
11 person authorized to handle controlled substances under the
12 laws of the United States and of this State.

13 (qq-5) "Secretary" means, as the context requires, either
14 the Secretary of the Department or the Secretary of the
15 Department of Financial and Professional Regulation, and the
16 Secretary's designated agents.

17 (rr) "State" includes the State of Illinois and any state,
18 district, commonwealth, territory, insular possession thereof,
19 and any area subject to the legal authority of the United
20 States of America.

21 (rr-5) "Stimulant" means any drug that (i) causes an
22 overall excitation of central nervous system functions, (ii)
23 causes impaired consciousness and awareness, and (iii) can be
24 habit-forming or lead to a substance use disorder, including,
25 but not limited to, amphetamines and their analogs,
26 methylphenidate and its analogs, cocaine, and phencyclidine

1 and its analogs.

2 (rr-10) "Synthetic drug" includes, but is not limited to,
3 any synthetic cannabinoids or piperazines or any synthetic
4 cathinones as provided for in Schedule I.

5 (ss) "Ultimate user" means a person who lawfully possesses
6 a controlled substance for his or her own use or for the use of
7 a member of his or her household or for administering to an
8 animal owned by him or her or by a member of his or her
9 household.

10 (Source: P.A. 102-389, eff. 1-1-22; 102-538, eff. 8-20-21;
11 102-813, eff. 5-13-22; 103-881, eff. 1-1-25.)

12 Section 999. Effective date. This Act takes effect upon
13 becoming law.